{"id":"https://openalex.org/W2137758263","doi":"https://doi.org/10.1200/jco.2006.07.2066","title":"Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors","display_name":"Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors","alternate_titles":[],"publication_year":2007,"publication_date":"2007-07-18","ids":{"openalex":"https://openalex.org/W2137758263","doi":"https://doi.org/10.1200/jco.2006.07.2066","mag":"2137758263","pmid":"https://pubmed.ncbi.nlm.nih.gov/17634482"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2006.07.2066","doi":"https://doi.org/10.1200/jco.2006.07.2066","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.07.2066","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2137758263"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037655243","display_name":"Joachim Drevs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Joachim Drevs","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061256281","display_name":"Patrizia Siegert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Patrizia Siegert","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031067983","display_name":"Michael Medinger","orcid":"https://orcid.org/0000-0003-0427-7747","observed_orcids":["https://orcid.org/0000-0003-0427-7747"]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Michael Medinger","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112408355","display_name":"Klaus B. Mross","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Klaus Mross","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047860622","display_name":"Ralph Strecker","orcid":"https://orcid.org/0000-0002-8232-8952","observed_orcids":["https://orcid.org/0000-0002-8232-8952"]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ralph Strecker","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053354533","display_name":"Ute Zirrgiebel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ute Zirrgiebel","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113453226","display_name":"Jan Harder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jan Harder","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110183079","display_name":"Hubert Erich Blum","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hubert Blum","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111162935","display_name":"Jane D. Robertson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jane Robertson","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087689900","display_name":"Juliane Margarete J\u00fcrgensmeier","orcid":"https://orcid.org/0000-0001-8438-2429","observed_orcids":["https://orcid.org/0000-0001-8438-2429"]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Juliane M. J\u00fcrgensmeier","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069409328","display_name":"Thomas A. Puchalski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Thomas A. Puchalski","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057087189","display_name":"Helen E. Young","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Helen Young","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036610271","display_name":"Owain Saunders","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Owain Saunders","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064684263","display_name":"Clemens Unger","orcid":"https://orcid.org/0000-0003-0461-2488","observed_orcids":["https://orcid.org/0000-0003-0461-2488"]},"institutions":[{"id":"https://openalex.org/I161046081","display_name":"University of Freiburg","ror":"https://ror.org/0245cg223","country_code":"DE","type":"education","lineage":["https://openalex.org/I161046081"]},{"id":"https://openalex.org/I2801240073","display_name":"University Medical Center Freiburg","ror":"https://ror.org/03vzbgh69","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2801240073"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Clemens Unger","raw_affiliation_strings":["From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Tumor Biology Center; MR Development and Application Center, Albert Ludwigs University; ProQinase GmbH; University Hospital, Freiburg, Germany; AstraZeneca, Macclesfield, Cheshire, United Kingdom; and AstraZeneca, Wilmington, DE","institution_ids":["https://openalex.org/I161046081","https://openalex.org/I2801240073"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":12.472,"has_fulltext":false,"cited_by_count":318,"citation_normalized_percentile":{"value":0.99503134,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"25","issue":"21","first_page":"3045","last_page":"3054"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/azd2171","display_name":"AZD2171","score":0.996999979019165},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.7369999885559082},{"id":"https://openalex.org/keywords/vegfr-tyrosine-kinase-inhibitors","display_name":"VEGFR inhibitors","score":0.8149999976158142},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.6380000114440918},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9610000252723694},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.9879999756813049},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7889999747276306},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9620000123977661},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.9509999752044678},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9629999995231628},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9639999866485596},{"id":"https://openalex.org/keywords/dynamic-contrast-enhanced-mri","display_name":"dynamic contrast-enhanced MRI","score":0.8690000176429749},{"id":"https://openalex.org/keywords/soluble-vegf-receptor-2","display_name":"soluble VEGF receptor-2","score":0.8539999723434448},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8230000138282776},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8379999995231628}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.895780086517334},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8212882280349731},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7198033332824707},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7032661437988281},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5809683203697205},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5385682582855225},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5317790508270264},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.5155148506164551},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.5062455534934998},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4947042167186737},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48560041189193726},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3903655409812927},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3816257119178772},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36146271228790283},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3442866802215576},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.30462217330932617},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.21776676177978516},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D015999","descriptor_name":"Multivariate Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2006.07.2066","doi":"https://doi.org/10.1200/jco.2006.07.2066","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.07.2066","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:17634482","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17634482","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1507842220","https://openalex.org/W1966486441","https://openalex.org/W1973918329","https://openalex.org/W1980969801","https://openalex.org/W1982246723","https://openalex.org/W2008632796","https://openalex.org/W2012859221","https://openalex.org/W2043863730","https://openalex.org/W2047470479","https://openalex.org/W2053704719","https://openalex.org/W2062594120","https://openalex.org/W2079503326","https://openalex.org/W2091872802","https://openalex.org/W2097373408","https://openalex.org/W2100785570","https://openalex.org/W2104311705","https://openalex.org/W2105677187","https://openalex.org/W2109747041","https://openalex.org/W2114682727","https://openalex.org/W2135836172","https://openalex.org/W2139248078","https://openalex.org/W2147178092","https://openalex.org/W2150374672","https://openalex.org/W2152099731","https://openalex.org/W2156121263","https://openalex.org/W2157769714","https://openalex.org/W2158316748","https://openalex.org/W2167368130","https://openalex.org/W2246879735","https://openalex.org/W2280283394","https://openalex.org/W2305352133"],"related_works":["https://openalex.org/W2591385705","https://openalex.org/W2605007591","https://openalex.org/W2268195585","https://openalex.org/W50056423","https://openalex.org/W2339800992","https://openalex.org/W2143695921","https://openalex.org/W2228204672","https://openalex.org/W3009296135","https://openalex.org/W2589183319","https://openalex.org/W2084863129"],"abstract_inverted_index":{"PURPOSE:":[0],"AZD2171":[1,62,100,161,277],"is":[2],"a":[3,169,198,299],"highly":[4],"potent":[5],"oral":[6,61,276],"selective":[7],"inhibitor":[8],"of":[9,28,31,36,132,163,197,204,252,280,302],"vascular":[10],"endothelial":[11],"growth":[12],"factor":[13],"(VEGF)":[14],"signaling.":[15],"This":[16],"phase":[17],"I":[18],"study":[19],"was":[20,77,118,126,153,181,285,290],"designed":[21],"to":[22,56,64,97,184,270],"evaluate":[23],"the":[24,74,137,219,228],"safety":[25],"and":[26,39,52,147,166,212,241,259,289],"tolerability":[27],"increasing":[29],"doses":[30,131,162,279],"AZD2171,":[32,124],"with":[33,49,83,188,194,262,292,298],"additional":[34],"assessments":[35,208],"pharmacokinetics,":[37],"pharmacodynamics,":[38],"efficacy.":[40],"PATIENTS":[41],"AND":[42],"METHODS:":[43],"In":[44,79,106],"part":[45,80],"A,":[46],"36":[47],"patients":[48,82,122,261,297],"solid":[50,304],"tumors":[51],"liver":[53,92],"metastases":[54,93],"refractory":[55],"standard":[57],"therapies":[58],"received":[59,123],"once-daily":[60,99],"(0.5":[63],"60":[65,223],"mg).":[66,105],"Doses":[67],"were":[68,94,144],"escalated":[69],"in":[70,215,227,244,296],"successive":[71],"cohorts":[72],"until":[73,111],"maximum-tolerated":[75],"dose":[76,272],"identified.":[78],"B,":[81],"(n":[84,89,155],"=":[85,90,156],"36)":[86],"or":[87,103,114,135,283],"without":[88],"11)":[91],"randomly":[95],"assigned":[96],"receive":[98],"(20,":[101],"30,":[102],"45":[104,133,281],"both":[107],"parts,":[108],"treatment":[109],"continued":[110],"tumor":[112,267],"progression":[113],"dose-limiting":[115],"toxicity":[116],"(DLT)":[117],"observed.":[119],"RESULTS:":[120],"Eighty-three":[121],"which":[125,158],"generally":[127,286],"well":[128,238,287],"tolerated":[129,288],"at":[130,160,278],"mg/d":[134],"less;":[136],"most":[138,150],"frequently":[139],"reported":[140],"dose-related":[141],"adverse":[142],"events":[143],"diarrhea,":[145],"dysphonia,":[146],"hypertension.":[148],"The":[149],"common":[151],"DLT":[152],"hypertension":[154],"7),":[157],"occurred":[159],"20":[164],"mg":[165,282],"higher.":[167],"After":[168],"single":[170],"dose,":[171],"maximum":[172],"plasma":[173],"(peak)":[174],"drug":[175],"concentration":[176],"after":[177],"single-dose":[178],"administration":[179],"(Cmax)":[180],"achieved":[182],"1":[183],"8":[185],"hours":[186],"postdosing":[187],"an":[189],"arithmetic":[190],"mean":[191],"half-life":[192],"associated":[193,291],"terminal":[195],"slope":[196],"semilogarithmic":[199],"concentration-time":[200],"curve":[201],"(t1/2":[202],"lamda(z))":[203],"22":[205,260],"hours.":[206],"Pharmacodynamic":[207],"demonstrated":[209],"time-,":[210],"dose-,":[211],"exposure-related":[213],"decreases":[214],"initial":[216],"area":[217],"under":[218],"curve,":[220],"defined":[221],"over":[222],"seconds":[224],"post-contrast":[225],"arrival":[226],"tissue":[229],"(iAUC60)":[230],"using":[231],"dynamic":[232],"contrast-enhanced":[233],"magnetic":[234],"resonance":[235],"imaging,":[236],"as":[237,239],"dose-":[240],"time-dependent":[242],"reductions":[243],"soluble":[245],"VEGF":[246],"receptor":[247],"2":[248],"levels.":[249],"Preliminary":[250],"evidence":[251],"efficacy":[253],"included":[254],"two":[255],"confirmed":[256],"partial":[257],"responses":[258],"stable":[263],"disease;":[264],"effects":[265],"on":[266],"size":[268],"appeared":[269],"be":[271],"related.":[273],"CONCLUSION:":[274],"Once-daily":[275],"less":[284],"encouraging":[293],"antitumor":[294],"activity":[295],"broad":[300],"range":[301],"advanced":[303],"tumors.":[305]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2137758263","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":22},{"year":2015,"cited_by_count":19},{"year":2014,"cited_by_count":23},{"year":2013,"cited_by_count":30},{"year":2012,"cited_by_count":29}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
